The following summary of CenterWatch’s 2019 Global Site Relationship Survey presents sites’ views on the CROs they work with. In last month’s issue, we provided details on their sponsor relationship views, as well as data on the types, locations and therapeutic areas of the site responding to the survey (CenterWatch Monthly, November 2019).
Sites are looking for improvements in almost all areas of their working relationships with CROs, but particularly in the areas of contracting and budget, according to a new CenterWatch survey.
For the second year in a row Novartis has been named the most innovative pharma company in the industry by the Innovation Index, a collaboration between CNS Summit and IDEA Pharma.
“The differentiator between Novartis and the competition was the nature of these innovative initiatives, which showed strong potential to be transformative, rather than incremental,” said a report on the index, which measures companies’ advances in trial optimization, clinical innovation and use of digital technology.
CenterWatch analyzes data in its drug intelligence database to provide advance notice of clinical trials expected to enter the next phase of clinical development soon. Contact information is provided for follow up. Sponsors/CROs: to list an upcoming trial here, contact Leslie Ramsey, 703.538.7600, email@example.com; or to initiate a search to identify sites for an upcoming or currently active trial, email firstname.lastname@example.org or submit online at centerwatch.com/clinical-trials/trialwatch/. Sites: to be matched to sponsor/CRO requests, submit a brief online profile at centerwatch.com/news-resources/trialwatch/.